Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

BACKGROUND AND AIMS: Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderat...

Descripción completa

Detalles Bibliográficos
Autores principales: Loftus, Edward V, Vermeire, Séverine, Feagan, Brian G, Le Brun, Franck-Olivier, Oortwijn, Alessandra, Moerch, Ulrik, Sandborn, William J, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024544/
https://www.ncbi.nlm.nih.gov/pubmed/36006011
http://dx.doi.org/10.1093/ecco-jcc/jjac122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024544/
https://www.ncbi.nlm.nih.gov/pubmed/36006011
http://dx.doi.org/10.1093/ecco-jcc/jjac122

Ejemplares similares